 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

NX-13, a Novel, Oral, NLRX1 Agonist, was Observed to be Well Tolerated and Demonstrated Early Signs of Rapid Symptomatic Relief and Endoscopic Improvement in Patients with Ulcerative Colitis NEXUS...

Landos Biopharma Publishes Results of NX-13 Phase 1b Study in Ulcerative Colitis in Journal of Crohn's and Colitis

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Arcellx Inc (ACLX Research Report), Afya (AFYA...

Analysts Have Conflicting Sentiments on These Healthcare Companies: Arcellx Inc (ACLX), Afya (AFYA) and Landos Biopharma (LABP)

NEXUS Phase 2 Clinical Trial of NX-13 for Ulcerative Colitis Remains On Track with Top-line Results Planned for Q4 2024 Sufficient Cash to Fund Planned Operations into First Half of 2025...

Landos Biopharma Provides Company Update and Reports Third Quarter 2023 Results

Shares of Landos Biopharma, Inc. (NASDAQ:LABP  Get Free Report) fell 1% on Tuesday . The company traded as low as $3.49 and last traded at $3.80. 13,795 shares traded hands during trading, a...

Landos Biopharma (NASDAQ:LABP)  Shares Down 1%

Collaboration Will Focus on Defining the Effects Of NX-13 in Ulcerative Colitis Patient Derived Organoid ModelsNEW YORK, Sept. 14, 2023 (GLOBE NEWSWIRE) -- Landos Biopharma, Inc. (NASDAQ: LABP), a...

Landos Biopharma Announces Strategic Research Collaboration with KU Leuven and University Hospitals Leuven to Further Characterize the Effects of NX-13 on Epithelial Cells

Landos Biopharma, Inc. (NASDAQ:LABP Free Report) Investment analysts at Leerink Partnrs lifted their Q3 2023 earnings per share (EPS) estimates for shares of Landos Biopharma in a note issued to investors on Thursday, August 10th. Leerink Partnrs analyst T. Smith now expects that the company will ...

Landos Biopharma, Inc. (NASDAQ:LABP) Expected to Earn Q3 2023 Earnings of ($0.79) Per Share

Initiated NEXUS Phase 2 Clinical Trial of NX-13 for Ulcerative Colitis NEXUS Remains On Track With Top-line Results Planned for Q4 2024 Sufficient Cash to Fund Planned Operations into First Half of 2025 NEW YORK, Aug. 09, 2023 (GLOBE NEWSWIRE) -- Landos Biopharma, Inc. (NASDAQ: LABP), a clinical-...

Landos Biopharma Provides Business Update & Reports Second Quarter 2023 Results

Landos Biopharma, Inc. (NASDAQ:LABP  Get Free Report) saw a significant decline in short interest in June. As of June 30th, there was short interest totalling 18,900 shares, a decline of 10.0% from the June 15th total of 21,000 shares. Currently, 0.7% of the shares of the stock are sold short...

Landos Biopharma, Inc. (NASDAQ:LABP) Short Interest Down 10.0% in June

Landos Biopharma, Inc. (NASDAQ:LABP Get Free Report) was the target of a large decline in short interest in the month of June. As of June 30th, there was short interest totalling 18,900 shares, a decline of 10.0% from the June 15th total of 21,000 shares. Based on an average daily volume of 23,400 ...

Short Interest in Landos Biopharma, Inc. (NASDAQ:LABP) Drops By 10.0%

NEW YORK, May 31, 2023 (GLOBE NEWSWIRE) -- Landos Biopharma, Inc. (NASDAQ: LABP), a clinical-stage biopharmaceutical company developing novel, oral medicines for patients with autoimmune diseases, today announced that it will participate at the Jefferies Healthcare Conference, to be held from June 7...

Landos Biopharma to Present at the 2023 Jefferies Healthcare Conference

Landos Biopharma, Inc. is a clinical-stage biopharmaceutical company, which focuses on the development of novel, oral, once-daily therapeutics for patients with certain immunology diseases. It offers NX-13, a novel, oral, gut-restricted compound for the treatment of inflammatory bowel disease, which targets the NLRX1 pathway. The firm's preclinical candidates include LABP-73, LABP-66, and LABP-69. The company was founded by Josep Bassaganya-Riera in January 2017 and is headquartered in Blacksburg, VA.

Watchers	601
52-Wk Low	$2.11
52-Wk High	$6.20

Market Cap	$13.15M
Volume (M)	25,847.00
52-Wk High	$6.20
52-Wk Low	$2.11

LABP Landos Biopharma Inc

About

Feed

News

Sentiment

Fundamentals